Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition

References

• Valter K, Zhivotovsky B, Gogvadze V. Cell death-based treatment of neuroblastoma. Cell Death Dis. 2018;9:113. doi:10.1038/s41419-018-1111-y.
   PubMed Web of Science ®Google Scholar
• Davidoff A. Neuroblastoma. Semin Pediatr Surg. 2012;21:2–14. doi:10.1053/j.sempedsurg.2011.10.009.
   PubMed Web of Science ®Google Scholar
• Ara T, DeClerck YA. Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Rev. 2006;25:645–657. doi:10.1007/s10555-006-9028-9.
   PubMed Web of Science ®Google Scholar
• Megison ML, Gillory LA, Beierle EA. Cell survival signaling in neuroblastoma. Anticancer Agents Med Chem. 2013;13:563–575.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–726. doi:10.1038/nrc3599.
   PubMed Web of Science ®Google Scholar
• Piskareva O, Harvey H, Nolan J, Conlon R, Alcock L, Buckley P, Dowling P, Henry M, O’Sullivan F, Bray I, et al. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. Cancer Lett. 2015;364:142–155. doi:10.1016/j.canlet.2015.05.004.
   PubMed Web of Science ®Google Scholar
• Zage PE, Sirisaengtaksin N, Liu Y, Gireud M, Brown BS, Palla S, Richards KN, Hughes DPM, Bean AJ. UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors. Cancer. 2013;119:915–923. doi:10.1002/cncr.27785.
   PubMed Web of Science ®Google Scholar
• Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology. 2011;25:85–101. doi:10.1152/physiol.00045.2009.
   Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787–2799. doi:10.1200/JCO.2003.01.504.
   PubMed Web of Science ®Google Scholar
• Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res. 2007;67:8240–8247. doi:10.1158/0008-5472.CAN-07-0589.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369–385. doi:10.1053/j.seminoncol.2006.04.003.
   PubMed Web of Science ®Google Scholar
• Zage PE, Bean AJ. Growth factor receptor trafficking as a potential therapeutic target in pediatric cancer. Front Biol 2012;7:1–13. doi:10.1007/s11515-011-1181-z.
   Google Scholar
• Zheng C, Shen R, Li K, Zheng N, Zong Y, Ye D, Wang Q, Wang Z, Chen L, Ma Y. Epidermal growth factor receptor is overexpressed in neuroblastoma tissues and cells. Acta Biochim Biophys Sin (Shanghai). 2016;48:762–767. doi:10.1093/abbs/gmw064.
   PubMed Web of Science ®Google Scholar
• Woodfield SE, Guo R, Liu Y, Major A, Hollingsworth E, Indiviglio S, Whittle S, Mo Q, Bean A, Ittmann M, et al. Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B. Genes Cancer. 2016;7:13–26.
   PubMedGoogle Scholar
• Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and Outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011;56:578–583. doi:10.1002/pbc.22696.
   PubMed Web of Science ®Google Scholar
• Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014;24:26–34. doi:10.1016/j.tcb.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Henriksen L, Grandal MV, Knudsen SLJ, van Deurs B, Grøvdal LM. Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. PLoS One. 2013;8:e58148. doi:10.1371/journal.pone.0058148.
   PubMed Web of Science ®Google Scholar
• Gruenberg J. The endocytic pathway: a mosaic of domains. Nat Rev Mol Cell Biol 2001;2:721–730. doi:10.1038/35096054.
   PubMed Web of Science ®Google Scholar
• Wong C, Mcnally C. EGF receptor ubiquitination is not necessary for its internalization. Proc Natl Acad Sci 2007;104:16904–16909. doi:10.1073/pnas.0707416104.
   PubMed Web of Science ®Google Scholar
• Sirisaengtaksin N, Gireud M, Yan Q, Kubota Y, Meza D, Waymire JC, Zage PE, Bean AJ. UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation. J Biol Chem 2014;289:3026–3039. doi:10.1074/jbc.M113.495671.
   PubMed Web of Science ®Google Scholar
• Eden ER, Huang F, Sorkin A, Futter CE. The role of EGF receptor ubiquitination in regulating its intracellular traffic. Traffic. 2012;13:329–337. doi:10.1111/j.1600-0854.2011.01305.x.
   PubMed Web of Science ®Google Scholar
• Marmor MD, Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene. 2004;23:2057–2070. doi:10.1038/sj.onc.1207444.
   PubMed Web of Science ®Google Scholar
• Sun W, Vida TA, Sirisaengtaksin N, Merrill SA, Hanson PI, Bean AJ. Cell-free reconstitution of multivesicular body formation and receptor sorting. Traffic. 2010;11:867–876. doi:10.1111/tra.2010.11.issue-6.
   PubMed Web of Science ®Google Scholar
• Mouneimne G, Hansen S, Selfors L, Petrak L, Hickey M, Gallegos L, Simpson K, Lim J, Gertler F, Hartwig J, et al. Differential remodeling of actin cytoskeleton architecture by profilin isoforms leads to distinct effects on cell migration and invasion. Cancer Cell. 2012;22:615–630. doi:10.1016/j.ccr.2012.09.027.
   PubMed Web of Science ®Google Scholar
• Gireud-Goss M, Reyes S, Wilson M, Farley M, Memarzadeh K, Srinivasan S, Sirisaengtaksin N, Yamashita S, Tsunoda S, Lang FF, et al. Distinct mechanisms enable inward or outward budding from late endosomes/multivesicular bodies. Exp Cell Res. 2018;372:1–15. doi:10.1016/J.YEXCR.2018.08.027.
   PubMed Web of Science ®Google Scholar
• Rössler J, Odenthal E, Geoerger B, Gerstenmeyer A, Lagodny J, Niemeyer CM, Vassal G. EGFR inhibition using gefitinib is not active in neuroblastoma cell lines. Anticancer Res. 2009;29:1327–1334.
   PubMed Web of Science ®Google Scholar
• Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage PE, Hughes DPM. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer. 2010;116:3233–3243. doi:10.1002/cncr.v116:13.
   PubMed Web of Science ®Google Scholar
• Du C, Wu H, Leng RP. UBE4B targets phosphorylated p53 at serines 15 and 392 for degradation. 2015;7:2823–2836.
   Google Scholar
• Carén H, Fransson S, Ejeskär K, Kogner P, Martinsson T. Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br J Cancer. 2007;97:1416–1424. doi:10.1038/sj.bjc.6604032.
   PubMed Web of Science ®Google Scholar
• Song S, Honjo S, Jin J, Chang -S-S, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et al. The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res 2015;21:2580–2590. doi:10.1158/1078-0432.CCR-14-2191.
   PubMed Web of Science ®Google Scholar
• Pozzi C, Cuomo A, Spadoni I, Magni E, Silvola A, Conte A, Sigismund S, Ravenda PS, Bonaldi T, Zampino MG, et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat Med 2016;22:624–631. doi:10.1038/nm.4078.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–345. doi:10.1056/NEJMcp041956.
   PubMed Web of Science ®Google Scholar
• Thiele CJ. Neuroblastoma cell lines. Hum Cell. 1998;1:21–53.
   Google Scholar
• Kalliokoski T, Kramer C, Vulpetti A, Gedeck P, Cavalli A. Comparability of mixed IC50 data - a statistical analysis. PLoS One. 2013;8:e61007. doi:10.1371/journal.pone.0061007.
   PubMed Web of Science ®Google Scholar
• Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur GM. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 2005;65:9868–9875. doi:10.1158/0008-5472.CAN-04-4557.
   PubMed Web of Science ®Google Scholar
• Quesnelle KM, Boehm AL, Grandis JR. STAT‐mediated EGFR signaling in cancer. J Cell Biochem 2007;102:311–319. doi:10.1002/(ISSN)1097-4644.
   PubMed Web of Science ®Google Scholar
• Schafranek L,  Nievergall E, Powell JA, Hiwase DK, Leclercq T, Hughes TP, White DL. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia. 2015;29:76–85. doi:10.1038/leu.2014.245.
   PubMed Web of Science ®Google Scholar
• Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018;1–12. doi:10.1038/s41375-017-0005-9.
   Google Scholar
• Mohanty SK, Yagiz K, Pradhan D, Luthringer DJ, Amin MB, Alkan S, Cinar B. STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget. 2017;8:85997–86010. doi:10.18632/oncotarget.v8i49.
   PubMedGoogle Scholar
• Roos A, Dhruv HD, Peng S, Inge LJ, Tuncali S, Pineda M, Millard N, Mayo Z, Eschbacher JM, Loftus JC, et al. EGFRvIII–stat5 signaling enhances glioblastoma cell migration and survival. Mol Cancer Res 2018;16:1185–1195. doi:10.1158/1541-7786.MCR-18-0125.
   PubMed Web of Science ®Google Scholar
• Koppikar P, Lui VWY, Man D, Xi S, Chai RL, Nelson E, Tobey ABJ, Grandis JR. Constitutive activation of STAT5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to EGFR targeting. Clin Cancer Res. 2008;14:7682–7690. doi:10.1158/1078-0432.CCR-08-1328.
   PubMed Web of Science ®Google Scholar
• Van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res Rev Mutat Res 2011;728:23–34. doi:10.1016/j.mrrev.2011.05.002.
   PubMed Web of Science ®Google Scholar
• Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst. 2001;93:1375–1384. doi:10.1093/jnci/93.18.1375.
   PubMed Web of Science ®Google Scholar
• Caron H, van Sluis P, de Kraker J, Bökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voûte PA, Versteeg R. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225–230. doi:10.1056/NEJM199606133342404.
   PubMed Web of Science ®Google Scholar
• Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243–2253. doi:10.1056/NEJMoa052399.
   PubMed Web of Science ®Google Scholar
• Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, Rajalingam V, Gerbing R, Stram DO, Matthay KK, et al. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol 2001;36:32–36. doi:10.1002/(ISSN)1096-911X.
   PubMedGoogle Scholar
• Hatakeyama S, Yada M, Matsumoto M, Ishida N, Nakayama KI. U box proteins as a new family of ubiquitin-protein ligases. J Biol Chem 2001;276:33111–33120. doi:10.1074/jbc.M102755200.
   PubMedGoogle Scholar
• Krona C, Ejeskär K, Abel F, Kogner P, Bjelke J, Björk E, Sjöberg R-M, Martinsson T. Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene. 2003;22:2343–2351. doi:10.1038/sj.onc.1206324.
   PubMed Web of Science ®Google Scholar
• Carén H, Ejeskär K, Fransson S, Hesson L, Latif F, Sjöberg R-M, Krona C, Martinsson T. A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation. Mol Cancer. 2005;4:10. doi:10.1186/1476-4598-4-10.
   PubMed Web of Science ®Google Scholar
• Trippett TM, Herzog C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, Hunger SP, Boklan J, Smith AA, Arceci RJ, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: A study of the pediatric oncology experimental therapeutic investigators’ consortium. J Clin Oncol. 2009;27:5102–5108. doi:10.1200/JCO.2008.20.8975.
   PubMed Web of Science ®Google Scholar
• Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000–2008. doi:10.1038/sj.onc.1205260.
   PubMed Web of Science ®Google Scholar
• Hatakeyama S. Ubiquitin-mediated regulation of JAK-STAT signaling in embryonic stem cells. Jak-Stat. 2012;1:168–175. doi:10.4161/jkst.21560.
   PubMedGoogle Scholar
• Dowlati A, Nethery D, Kern JA. Combined inhibition of epidermal growth factor receptor and JAK / STAT pathways results in greater growth inhibition in vitro than single agent therapy Combined inhibition of epidermal growth factor receptor and JAK / STAT pathways results in greater grow. 2004:3(4):459–463.
   Google Scholar
• Darnell J, Kerr I, Stark G. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (80-). 1994;264:1415–1421. doi:10.1126/science.8197455.
   PubMed Web of Science ®Google Scholar
• Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281–1283. doi:10.1242/jcs.00963.
   PubMed Web of Science ®Google Scholar
• Barash I. Stat5 in breast cancer: potential oncogenic activity coincides with positive prognosis for the disease. Carcinogenesis. 2012;33:2320–2325. doi:10.1093/carcin/bgs362.
   PubMed Web of Science ®Google Scholar
• Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117:3409–3420. doi:10.1182/blood-2009-10-248211.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Pirker R, O'Byrne KJ, Kerr KM, Störkel S, von Heydebreck A, Grote HJ, Celik I, Shepherd FA. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9:717–724. doi:10.1097/JTO.0000000000000011.
   PubMed Web of Science ®Google Scholar
• Rouyer M, François E, Cunha AS, Monnereau A, Noize P, Robinson P, Droz-Perroteau C, Le Monies de Sagazan A, Jové J, Lassalle R, et al. Effectiveness of cetuximab as first-line therapy for patients with wild-type KRAS and unresectable metastatic colorectal cancer in real-life practice: results of the EREBUS cohort. Clin Colorectal Cancer. 2018;33:1–11.
   Google Scholar
• Karapetis C, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2015;372:311–319.
   PubMedGoogle Scholar
• Santuray RT, Johnson DE, Grandis JR. New therapies in head and neck cancer. Trends Cancer. 2018;4:385–396. doi:10.1016/j.trecan.2018.03.006.
   PubMed Web of Science ®Google Scholar
• Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drug. 2009;20:851–855. doi:10.1097/CAD.0b013e3283330590.
   Google Scholar
• Entschladen F, Drell TL VI, Lang K, Joseph J, Zaenker KS. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol. 2004;5:254–258. doi:10.1016/S1470-2045(04)01431-7.
   PubMed Web of Science ®Google Scholar
• Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. J Clin Oncol. 2009;27:298–303. doi:10.1200/JCO.2008.16.6876.
   PubMed Web of Science ®Google Scholar
• Hölsken A, Gebhardt M, Buchfelder M, Fahlbusch R, Blumcke I, Buslei R. EGFR signaling regulates tumor cell migration in craniopharyngiomas. Clin Cancer Res. 2011;17:4367–4377. doi:10.1158/1078-0432.CCR-10-2811.
   PubMed Web of Science ®Google Scholar
• Zhang L, Scorsone K, Woodfield SE, Zage PE. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemother Pharmacol 2015;76:977–987. doi:10.1007/s00280-015-2871-z.
   PubMed Web of Science ®Google Scholar